Ion Beam Applications SA
José Luis Roldán de Llano has a diverse work experience in various companies. José Luis started their career as a Service Engineer at Tecnología y Sistemas Didácticos in 1999. José Luis then moved on to Bioterra - Biología y Técnica de la Radiación, where they worked as a Service Manager from 2003 to 2006. Following this, they joined Eastman Kodak as a Key Account Manager in 2006. In 2007, they joined Carestream Health as a Key Account Manager. José Luis then joined IBA in 2008 and held several positions, including Area Sales Manager for Mediterranean Countries and EMEA, and finally, as the EMEA & LATAM Sales Director. Their tenure at IBA lasted until 2017 when they left the company.
José Luis Roldán de Llano has a Master's degree in ExMBA from IE Business School, which they obtained from 2007 to 2008. Prior to that, they studied Electronics Engineering at Universidad Complutense de Madrid from 1999 to 2001. José Luis also has a degree in Physics from Universidad de Santiago de Compostela, which they completed from 1993 to 1999. In addition to their formal education, José Luis has obtained several certifications, including courses in performance management, employee performance problems, career conversations, and productive meetings from LinkedIn. José Luis has also completed courses in marketing, finance, and child nutrition from Coursera.
This person is not in any offices
Ion Beam Applications SA
4 followers
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.